Sungmin Woo1, Chong Hyun Suh2, Andreas G Wibmer3, Anton S Becker3, Min Yuen Teo4, Mithat Gönen5, Hedvig Hricak3, Howard I Scher4, Michael J Morris4, Hebert Alberto Vargas3. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: woos@mskcc.org. 2. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Songpa-Gu, Seoul, Republic of Korea. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
INTRODUCTION/ BACKGROUND: Radiographic progression-free survival (rPFS) based on Prostate Cancer Working Group 2 (PCWG2) has been increasingly used as a meaningful imaging-based intermediate endpoint (IBIE) for overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). In randomized phase III trials, rPFS showed good correlation with OS at the individual trial level. We aimed to assess the correlation between the hazard ratios (HR) of IBIE and OS among PCWG2-based randomized trials. MATERIALS AND METHODS: PubMed and EMBASE databases were systematically searched for randomized trials evaluating systemic treatments on mCRPC using PCWG2 up to April 15, 2020. Hazard ratios for OS and IBIEs were extracted and their correlation was assessed using weighted linear regression. Subgroup analyses were performed according to various clinical settings: prior chemotherapy, drug category, type of IBIE (rPFS vs. composite IBIE, latter defined as progression by imaging and one or a combination of PSA, pain, skeletal-related events, and performance status), and publication year. RESULTS: Twenty-eight phase II-III randomized trials (16,511 patients) were included. Correlation between OS and IBIE was good (R2 = 0.57, 95% confidence interval [CI], 0.35-0.78). Trials using rPFS showed substantially higher correlation than those using a composite IBIE (R2 = 0.58, 95% CI, 0.32-0.82 vs. 0.00, 95% CI, -0.01 to 0.01). Correlations between OS and IBIE in other subgroups were at least moderate in nearly all subgroups (R2 = 0.32-0.91). CONCLUSION: IBIEs in the era of PCWG2 correlate well with OS in randomized trials for systemic drugs in patients with mCRPC. PCWG2-based rPFS should be used instead of a composite IBIE that includes PSA and other clinical variables.
INTRODUCTION/ BACKGROUND: Radiographic progression-free survival (rPFS) based on Prostate Cancer Working Group 2 (PCWG2) has been increasingly used as a meaningful imaging-based intermediate endpoint (IBIE) for overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). In randomized phase III trials, rPFS showed good correlation with OS at the individual trial level. We aimed to assess the correlation between the hazard ratios (HR) of IBIE and OS among PCWG2-based randomized trials. MATERIALS AND METHODS: PubMed and EMBASE databases were systematically searched for randomized trials evaluating systemic treatments on mCRPC using PCWG2 up to April 15, 2020. Hazard ratios for OS and IBIEs were extracted and their correlation was assessed using weighted linear regression. Subgroup analyses were performed according to various clinical settings: prior chemotherapy, drug category, type of IBIE (rPFS vs. composite IBIE, latter defined as progression by imaging and one or a combination of PSA, pain, skeletal-related events, and performance status), and publication year. RESULTS: Twenty-eight phase II-III randomized trials (16,511 patients) were included. Correlation between OS and IBIE was good (R2 = 0.57, 95% confidence interval [CI], 0.35-0.78). Trials using rPFS showed substantially higher correlation than those using a composite IBIE (R2 = 0.58, 95% CI, 0.32-0.82 vs. 0.00, 95% CI, -0.01 to 0.01). Correlations between OS and IBIE in other subgroups were at least moderate in nearly all subgroups (R2 = 0.32-0.91). CONCLUSION: IBIEs in the era of PCWG2 correlate well with OS in randomized trials for systemic drugs in patients with mCRPC. PCWG2-based rPFS should be used instead of a composite IBIE that includes PSA and other clinical variables.
Authors: Matthew Smith; Chris Parker; Fred Saad; Kurt Miller; Bertrand Tombal; Quan Sing Ng; Martin Boegemann; Vsevolod Matveev; Josep Maria Piulats; Luis Eduardo Zucca; Oleg Karyakin; Go Kimura; Nobuaki Matsubara; William Carlos Nahas; Franco Nolè; Eli Rosenbaum; Axel Heidenreich; Yoshiyuki Kakehi; Amily Zhang; Heiko Krissel; Michael Teufel; Junwu Shen; Volker Wagner; Celestia Higano Journal: Lancet Oncol Date: 2019-02-06 Impact factor: 41.316
Authors: Michael J Morris; Arturo Molina; Eric J Small; Johann S de Bono; Christopher J Logothetis; Karim Fizazi; Paul de Souza; Philip W Kantoff; Celestia S Higano; Jinhui Li; Thian Kheoh; Steven M Larson; Shannon L Matheny; Vahid Naini; Tomasz Burzykowski; Thomas W Griffin; Howard I Scher; Charles J Ryan Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: A J Armstrong; M Häggman; W M Stadler; J R Gingrich; V Assikis; J Polikoff; J E Damber; L Belkoff; Ö Nordle; G Forsberg; M A Carducci; R Pili Journal: Clin Cancer Res Date: 2013-11-19 Impact factor: 12.531
Authors: Johann S de Bono; Ugo De Giorgi; Daniel Nava Rodrigues; Christophe Massard; Sergio Bracarda; Albert Font; Jose Angel Arranz Arija; Kent C Shih; George Daniel Radavoi; Na Xu; Wai Y Chan; Han Ma; Steven Gendreau; Ruth Riisnaes; Premal H Patel; Daniel J Maslyar; Viorel Jinga Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: M Dror Michaelson; Stephane Oudard; Yen-Chuan Ou; Lisa Sengeløv; Fred Saad; Nadine Houede; Peter Ostler; Arnulf Stenzl; Gedske Daugaard; Robert Jones; Fredrik Laestadius; Anders Ullèn; Amit Bahl; Daniel Castellano; Juergen Gschwend; Tristan Maurina; Edna Chow Maneval; Shaw-Ling Wang; Maria Jose Lechuga; Jolanda Paolini; Isan Chen Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245